Global Drug Shortages; What are the causes and how do we fix them?

Fintan Walton, founder and CEO of PharmaVentures chairs a round table discussion on this pressing issue.

 

Featuring;

Jim Gale. Managing Partner, Signet Healthcare Partners. A New York based Private equity firm with a wide portfolio including API medchem, Pharma Services and CDMO businesses.

Andreas Raabe: Founder & CEO of Adragos Pharma, a CDMO manufacturing in the EU and Japan.

Frank Dollard: 45 years of experience in pharmaceutical manufacturing, including GSK, BMS and Teva.

Soren Demin: Managing Director & Head of M&A at PharmaVentures and formerly senior commercial positions in multiple pharma business and a qualified medical practitioner.

 

In a wide-ranging discussion, hear the panelist's views on;

1. What is meant by "drug shortages" and where has the system failed?
2. Where are the pinch points; manufacture, supply chains, pharma-centric influences, geopolitical events?
3. The impact on manufacturers of the US Biosecure Act.
4. The knock-on effects of pricing pressure on raw material sourcing.
5. Increasing capacity & the role of M&A
6. Can technology and innovation solve the problems?
7. Where are the opportunities emerging from that will provide the solutions?